首页> 外文期刊>Cureus. >Emphysematous Cholecystitis Secondary to Fusobacterium nucleatum
【24h】

Emphysematous Cholecystitis Secondary to Fusobacterium nucleatum

机译:顽固性胆囊炎继发于核心核

获取原文
           

摘要

Fusobacterium nucleatum may be implicated in cases of emphysematous cholecystitis (EC) and carries a high mortality risk, especially in individuals with heart disease, renal insufficiency, and underlying malignancy. Fusobacterium?infections are rarely detected in the setting of cholecystitis possibly due to the difficulty with properly culturing the bacteria. We describe a case of a patient with EC in whom blood cultures were positive for growth of F.?nucleatum in one of two samples. The patient was treated with empiric antibiotic therapy consisting of metronidazole and cefepime. In patients with EC and negative cultures, it is possible that they may have an undetected infection with fusobacteria, which carries a high mortality risk. As such, clinicians should maintain a high degree of suspicion of obligate anaerobic infection in patients who have negative blood culture for growth in the setting of EC and consider continuation of adequate antimicrobial coverage.
机译:在顽育胆囊炎(EC)的情况下,核酸杆菌患者可能涉及,并且具有高死亡率风险,特别是在心脏病,肾功能不全和潜在恶性肿瘤的个体中。 由于适当培养细菌的困难,在胆囊炎的设置中,很少检测到fusobacterium?感染可能是由于胆囊炎的困难。 我们描述了患有EC的患者,其中血液培养为F.nucleatum在两个样品之一中的生长阳性。 患者用核苷酰胺和头孢噻肟组成的经验抗生素治疗治疗。 在EC和阴性培养的患者中,它们可能具有未检测到的Fusobacteria感染,其具有高死亡率风险。 因此,临床医生应保持对具有阴性血液培养的患者对EC的生长的患者进行高度怀疑,并考虑延续足够的抗微生物覆盖率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号